lol my typing a bit scrambled on my previous post on PRR. The stock has retraced a bit but is now building again. Dendreon approval came through and the hype washed off onto Prima Biomed PRR. This stock has potential as orphan status approval pending in Europe and result likely to be known first week in June and USA FDA orphan status approval even more important is also pending. Orphan status amongst other things extends the life of the patent.
